Delving into the Latest Updates on Moxonidine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2R,4R)-1-[(2S)-5-[(aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8- quinolinyl)sulfonyl]amino]pentyl]-4-methyl-2-piperidinecarboxylic acid, Moxodin, Moxonidine (USAN/INN)

+ [17]

Target

ADRA2

Mechanism

ADRA2 agonists(Adrenergic receptors alpha-2 agonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

DE (01 Jan 1991),

Hypertension

Regulation-

Login to view timeline

Structure

Molecular FormulaC9H12ClN5O

InChIKeyWPNJAUFVNXKLIM-UHFFFAOYSA-N

CAS Registry75438-57-2

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Start Date20 May 2022

Sponsor / Collaborator

Vanderbilt University Medical Center

CTRI/2021/11/038087 / Not yet recruitingNot ApplicableIIT

COMPARISON OF ORAL CLONIDINE AND MOXONIDINE ON SENSORY AND MOTOR CHARACTERISTICS OF SUBARACHNOID BLOCK

Start Date11 Dec 2021

Sponsor / Collaborator-

NCT04140721 / RecruitingEarly Phase 1IIT

Autonomic Determinants of Postural Tachycardia Syndrome (Chronic Pilot Study 2)

Postural tachycardia syndrome (POTS) is a relatively common condition affecting mostly otherwise healthy young women. These patients have high heart rate and disabling symptoms during standing. Quality of life may be poor. The sympathetic nerves in the autonomic nervous system help to maintain normal blood pressures and heart rates during activities of daily life.
The purpose of this study is to determine the importance of sympathetic activation as a cause of orthostatic symptoms. The investigators will assess the effects of a blood pressure medication (Moxonidine) on the symptoms during standing. Moxonidine lowers sympathetic activity. The investigators believe patients with high resting sympathetic activity might benefit from Moxonidine. It might reduce high heart rate and improve symptoms during standing. This study should help clinicians and the growing population of patients with POTS gain a better understanding of this disorder and find more personalized treatment.

Start Date31 Aug 2021

Sponsor / Collaborator

Vanderbilt University Medical Center

[+1]

100 Clinical Results associated with Moxonidine

Login to view more data

100 Translational Medicine associated with Moxonidine

Login to view more data

100 Patents (Medical) associated with Moxonidine

Login to view more data

617

Literatures (Medical) associated with Moxonidine

01 Dec 2024·Bioorganic Chemistry

Spatial metabolomics to discover hypertrophic scar relevant metabolic alterations and potential therapeutic strategies: A preliminary study

Article

Author: Zhang, Enyuan ; Jiang, Jingbin ; Zeng, Siqi ; Li, Jun ; Li, Jingyun ; Chen, Ling

Spatially mapping the metabolic remodeling of hypertrophic scar and surrounding normal skin tissues has the potential to enhance our comprehension of scar formation and aid in the advancement of therapeutic interventions. In this study, we employed matrix-assisted laser desorption/ionization (MALDI), a mass spectrometry imaging technique, to visualize the hierarchical distribution of metabolites within sections of hypertrophic scar and surrounding normal skin tissues. A comprehensive analysis identified a total of 1631 metabolites in these tissues. The top four classes that were identified included benzene and substituted derivatives, heterocyclic compounds, amino acids and its metabolites, and glycerophospholipids. In hypertrophic scar tissues, 22 metabolites were upregulated and 66 metabolites were downregulated. MetaboAnalyst pathway analysis indicated that glycerophospholipid metabolism was primarily associated with these altered 88 metabolites. Subsequently, six metabolites were selected, their spatial characteristics were analyzed, and they were individually added to the cell culture medium of primary hypertrophic scar fibroblasts. The preliminary findings of this study demonstrate that specific concentrations of 1-pyrrolidinecarboxamide, 2-benzylideneheptanal, glycerol trioleate, Lyso-PAF C-16, and moxonidine effectively inhibited the expressions of COL1A1, COL1A2, COL3A1, and ACTA2. These bioactive metabolites exhibit mild and non-toxic properties, along with favorable pharmacokinetics and pharmacodynamics, making them promising candidates for drug development. Consequently, this research offers novel therapeutic insights for hypertrophic scar treatment.

01 Dec 2024·Journal of Hypertension

Targeting the sympathetic nervous system with the selective imidazoline receptor agonist moxonidine for the management of hypertension: an international position statement

Review

Author: Schlaich, Markus P. ; Borghi, Claudio ; Taddei, Stefano ; Marketou, Maria ; Kiuchi, Marcio G. ; Sindone, Andrew ; Farcas, Anca ; Tsioufis, Konstantinos ; Ferri, Claudio ; Cooper, Mark ; Vintila, Ana Maria ; Chandrappa, Shukrath ; Parissis, John

Hypertension is often linked with metabolic risk factors that share common pathophysiological pathways. Despite wide-spread availability of multiple drug classes, optimal blood pressure (BP) control remains challenging. Increased central sympathetic outflow is frequently neglected as a critical regulator of both circulatory and metabolic pathways and often remains unopposed therapeutically. Selective imidazoline receptor agonists (SIRAs) effectively reduce BP with a favorable side effect profile compared with older centrally acting antihypertensive drugs. Hard outcome data in hypertension, such as prevention of stroke, heart and kidney diseases, are not available with SIRAs. However, in direct comparisons, SIRAs were as effective as angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, and diuretics in lowering BP. Other beneficial effects on metabolic parameters in hypertensive patients with concomitant overweight and obesity have been documented with SIRAs. Here we review the existing evidence on the safety and efficacy of moxonidine, a widely available SIRA, compared with common antihypertensive agents and provide a consensus position statement based on inputs from 12 experts from Europe and Australia on SIRAs in hypertension management.

10 Sep 2024·Biomedicines

Is Arterial Stiffness Interconnected with Cardiovascular Drug Prescription Patterns, Body Composition Parameters, and the Quality of Blood Pressure Regulation in Hypertensive Patients?

Article

Author: Gelemanović, Andrea ; Belančić, Andrej ; Radić, Mislav ; Radić, Josipa ; Vučković, Marijana ; Đogaš, Hana

BACKGROUNDArterial hypertension (AH) is a significant risk factor for cardiovascular disease and is associated with increased arterial stiffness, particularly as measured by pulse wave velocity (PWV). This study aims to explore the relationships between age groups, antihypertensive and new oral antidiabetic drugs, body composition, and arterial stiffness parameters in hypertensive patients.METHODSA single-center cross-sectional study was conducted including 584 participants who underwent 24 h ambulatory blood pressure monitoring (including central blood pressure (BP) and PWV measurement), body composition analysis, and provided medical history and current pharmacotherapy data.RESULTSThe study found that PWV was significantly higher in patients with poorly regulated BP in those aged 65 years and older. Significant PWV predictors included systolic BP, heart rate, peripheral mean arterial pressure, peripheral pulse pressure, augmentation index, calcium channel blockers, moxonidine, sodium-glucose co-transporter 2 inhibitors, urapidil, and statin prescription. Also, statistically significant negative correlations were found between PWV and visceral fat level, fat-free mass, and the percentage of muscle mass.CONCLUSIONSThe findings suggest that arterial stiffness is interconnected with peripheral and central blood pressure parameters, body composition parameters, and prescribed hypertensive and new antidiabetic drugs.

100 Deals associated with Moxonidine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05087	Moxonidine	C02AC05	DB09242

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypertension	DE	-	01 Jan 1991

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02355821 (COMPASS, CTgov)	Not Applicable	Bone Diseases, Metabolic \| Hypertension	114	Moxonidine (Moxonidine)	shtgjxpmtl(doptnlkomz) = eyibvrwutu iqmxhlurqa (vcfphgdanw, uurrzmsqcy - ouzpzioihr) View more	-	01 Sep 2021
				Bisoprolol (Bisoprolol)	shtgjxpmtl(doptnlkomz) = iltrfjazqu iqmxhlurqa (vcfphgdanw, njrxkwibcf - muxxciwyjt) View more
ESC2018	Not Applicable	-	-	Moxonidine	(wwpzamykuy) = eiqjfqdpqc hhxfyyvjhc (fdsaryfxou ) View more	-	27 Aug 2018
				Bisoprolol	(wwpzamykuy) = ofljlkcvsy hhxfyyvjhc (fdsaryfxou ) View more
NCT01504321 (Pubmed \| Front Physiol)	Phase 4	Polycystic Ovary Syndrome	48	Moxonidine	kauytejosq(sbwssuylzk) = rylulsaack kogfapkdqg (ghvygljfuo ) View more	-	01 Jan 2018
				Placebo	kauytejosq(sbwssuylzk) = yvpnglrfxw kogfapkdqg (ghvygljfuo ) View more